Vertex Pharmaceuticals Incorporated Stock News

VRTX earnings call for the period ending December 31, 2021.

Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q4 2021 Results - Earnings Call Transcript

Vertex Pharmaceuticals press release (NASDAQ:VRTX): Q4 Non-GAAP EPS of $3.37 beats by $0.08.Revenue of $2.07B (+27.0% Y/Y) beats by $60M.

Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Rank and ESP are still a solid combination to predict earnings beats.

AbbVie will be releasing Phase 2 data for its experimental Cystic Fibrosis (CF) drugs that could potentially compete with Vertex's drugs. VRTX stock may move up or down, inversely related to the AbbVi

AFT is a closed end fund focusing on leveraged loans. The vehicle provides for a natural inflation hedge given the floating rate nature of the underlying loans.

Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.

All of them have tremendous growth prospects.

Six large-cap companies will report earnings next week. These are: TSLA, URI, FCX, VRTX, STLD and BRO.

BMO has upgraded shares of Vertex Pharmaceuticals based on recent promising data for VX-147, its candidate for the rare kidney condition focal segmental glomerulosclerosis.

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as ArcBest (ARCB), Advanced Micro Devices (AMD), AGCO Corporation (AGC